Simvastatin treatment improves endothelial function and increases fibrinolysis in patients with hypercholestrolemia
Statins reduce cardiovascular events by cholesterol-lowering as well as nonlipid-related actions. Thrombin activatable fibrinolysis inhibitor (TAFI) is a recently identified independent risk factor of thrombosis. Endothelial dysfunction is also a strong predictor of cardiovascular events. The aim of...
Gespeichert in:
| Veröffentlicht in: | Journal of the National Medical Association 2006-04, Vol.98 (4), p.627-630 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 630 |
|---|---|
| container_issue | 4 |
| container_start_page | 627 |
| container_title | Journal of the National Medical Association |
| container_volume | 98 |
| creator | Guven, Gulay S Atalar, Enver Yavuz, Bunyamin Beyazit, Yavuz Kekilli, Murat Kilicarslan, Alparslan Sahiner, Levent Oz, Gul Ozer, Necla Aksoyek, Serdar Haznedaroglu, Ibrahim C Sozen, Tumay |
| description | Statins reduce cardiovascular events by cholesterol-lowering as well as nonlipid-related actions. Thrombin activatable fibrinolysis inhibitor (TAFI) is a recently identified independent risk factor of thrombosis. Endothelial dysfunction is also a strong predictor of cardiovascular events. The aim of this study was to assess the effects of simvastatin treatment on circulating TAFI concentrations and endothelial function in patients with hypercholesterolemia.
Thirty-five patients (19 female, mean age 48 +/- 7 years) with hyperlipidemia were recruited into the study. Simvastatin was administered, 40 mg daily, for eight weeks to all subjects. Study subjects did not receive any medication except for lipid-lowering therapy during the follow-up period. Endothelial function was evaluated by flow-mediated dilation (FMD) from the brachial artery of the patients. Plasma lipid parameters, TAFI levels and endothelial function were measured before and after simvastatin treatment.
Treatment with simvastatin showed a significant decrement in plasma total cholesterol, LDL cholesterol and triglyceride levels (p |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2569240</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1029337371</sourcerecordid><originalsourceid>FETCH-LOGICAL-p291t-ccf95b749488ab5fd7af3504c3dbc6607180da72762ad35c2e67fb0b6b1aec903</originalsourceid><addsrcrecordid>eNpdkU1LxDAQhoMo7vrxFyR48FZI89lcBFn8ggUP6rmkaWojbVKTdGX_vRFXUS8zMPPw8A6zB5alpKSgXJJ9sEQIi0Lyii7AUYyvCKFKMnYIFiXnmCDBlyA-2nGjYlLJOpiCUWk0LkE7TsFvTITGtT71ZrBqgN3sdLLeQeVaaJ3OdMxIZ5tgnR-20cY8hlN2ZUeE7zb1sN9OJujeDyamkOto1Qk46NQQzemuH4Pnm-un1V2xfri9X12tiwnLMhVad5I1gkpaVaphXStURxiimrSN5hyJskKtElhwrFrCNDZcdA1qeFMqoyUix-DyyzvNzWhanUMFNdRTsKMK29orW__dONvXL35TY8Ylpp-Ci50g-Lc5H1CPNmozDMoZP8eai0pwRsoMnv8DX_0cXD6uxiVFjFAqMnT2O85Pju9nkA_fhIwh</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>214053447</pqid></control><display><type>article</type><title>Simvastatin treatment improves endothelial function and increases fibrinolysis in patients with hypercholestrolemia</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>PubMed Central</source><creator>Guven, Gulay S ; Atalar, Enver ; Yavuz, Bunyamin ; Beyazit, Yavuz ; Kekilli, Murat ; Kilicarslan, Alparslan ; Sahiner, Levent ; Oz, Gul ; Ozer, Necla ; Aksoyek, Serdar ; Haznedaroglu, Ibrahim C ; Sozen, Tumay</creator><creatorcontrib>Guven, Gulay S ; Atalar, Enver ; Yavuz, Bunyamin ; Beyazit, Yavuz ; Kekilli, Murat ; Kilicarslan, Alparslan ; Sahiner, Levent ; Oz, Gul ; Ozer, Necla ; Aksoyek, Serdar ; Haznedaroglu, Ibrahim C ; Sozen, Tumay</creatorcontrib><description>Statins reduce cardiovascular events by cholesterol-lowering as well as nonlipid-related actions. Thrombin activatable fibrinolysis inhibitor (TAFI) is a recently identified independent risk factor of thrombosis. Endothelial dysfunction is also a strong predictor of cardiovascular events. The aim of this study was to assess the effects of simvastatin treatment on circulating TAFI concentrations and endothelial function in patients with hypercholesterolemia.
Thirty-five patients (19 female, mean age 48 +/- 7 years) with hyperlipidemia were recruited into the study. Simvastatin was administered, 40 mg daily, for eight weeks to all subjects. Study subjects did not receive any medication except for lipid-lowering therapy during the follow-up period. Endothelial function was evaluated by flow-mediated dilation (FMD) from the brachial artery of the patients. Plasma lipid parameters, TAFI levels and endothelial function were measured before and after simvastatin treatment.
Treatment with simvastatin showed a significant decrement in plasma total cholesterol, LDL cholesterol and triglyceride levels (p<0.05). Plasma TAFI levels were also significantly decreased after simvastatin treatment [median 17.0 (range 0.4-93.7) mcg/mL versus median 6.9 (range 0.8-63.0) mcg/mL, p<0.001]. Mean FMD was measured 7.7 +/- 2.5% at baseline and significantly improved after treatment (13.0 +/- 1.4%) (p=0.001).
Our findings of decreased TAFI levels may reflect the beneficial effect of simvastatin treatment on fibrinolysis, and improved endothelial function may suggest the improved future cardiovascular events in hyperlipidemic patients.</description><identifier>ISSN: 0027-9684</identifier><identifier>EISSN: 1943-4693</identifier><identifier>PMID: 16623076</identifier><identifier>CODEN: JNMAAE</identifier><language>eng</language><publisher>United States: Elsevier Limited</publisher><subject>Anticholesteremic Agents - therapeutic use ; Endothelium, Vascular - drug effects ; Endothelium, Vascular - physiopathology ; Female ; Fibrinolysis - drug effects ; Humans ; Hypercholesterolemia - drug therapy ; Hypercholesterolemia - physiopathology ; Male ; Middle Aged ; Prospective Studies ; Simvastatin - therapeutic use</subject><ispartof>Journal of the National Medical Association, 2006-04, Vol.98 (4), p.627-630</ispartof><rights>Copyright National Medical Association Apr 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2569240/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/214053447?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,53791,53793,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16623076$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Guven, Gulay S</creatorcontrib><creatorcontrib>Atalar, Enver</creatorcontrib><creatorcontrib>Yavuz, Bunyamin</creatorcontrib><creatorcontrib>Beyazit, Yavuz</creatorcontrib><creatorcontrib>Kekilli, Murat</creatorcontrib><creatorcontrib>Kilicarslan, Alparslan</creatorcontrib><creatorcontrib>Sahiner, Levent</creatorcontrib><creatorcontrib>Oz, Gul</creatorcontrib><creatorcontrib>Ozer, Necla</creatorcontrib><creatorcontrib>Aksoyek, Serdar</creatorcontrib><creatorcontrib>Haznedaroglu, Ibrahim C</creatorcontrib><creatorcontrib>Sozen, Tumay</creatorcontrib><title>Simvastatin treatment improves endothelial function and increases fibrinolysis in patients with hypercholestrolemia</title><title>Journal of the National Medical Association</title><addtitle>J Natl Med Assoc</addtitle><description>Statins reduce cardiovascular events by cholesterol-lowering as well as nonlipid-related actions. Thrombin activatable fibrinolysis inhibitor (TAFI) is a recently identified independent risk factor of thrombosis. Endothelial dysfunction is also a strong predictor of cardiovascular events. The aim of this study was to assess the effects of simvastatin treatment on circulating TAFI concentrations and endothelial function in patients with hypercholesterolemia.
Thirty-five patients (19 female, mean age 48 +/- 7 years) with hyperlipidemia were recruited into the study. Simvastatin was administered, 40 mg daily, for eight weeks to all subjects. Study subjects did not receive any medication except for lipid-lowering therapy during the follow-up period. Endothelial function was evaluated by flow-mediated dilation (FMD) from the brachial artery of the patients. Plasma lipid parameters, TAFI levels and endothelial function were measured before and after simvastatin treatment.
Treatment with simvastatin showed a significant decrement in plasma total cholesterol, LDL cholesterol and triglyceride levels (p<0.05). Plasma TAFI levels were also significantly decreased after simvastatin treatment [median 17.0 (range 0.4-93.7) mcg/mL versus median 6.9 (range 0.8-63.0) mcg/mL, p<0.001]. Mean FMD was measured 7.7 +/- 2.5% at baseline and significantly improved after treatment (13.0 +/- 1.4%) (p=0.001).
Our findings of decreased TAFI levels may reflect the beneficial effect of simvastatin treatment on fibrinolysis, and improved endothelial function may suggest the improved future cardiovascular events in hyperlipidemic patients.</description><subject>Anticholesteremic Agents - therapeutic use</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Endothelium, Vascular - physiopathology</subject><subject>Female</subject><subject>Fibrinolysis - drug effects</subject><subject>Humans</subject><subject>Hypercholesterolemia - drug therapy</subject><subject>Hypercholesterolemia - physiopathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prospective Studies</subject><subject>Simvastatin - therapeutic use</subject><issn>0027-9684</issn><issn>1943-4693</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdkU1LxDAQhoMo7vrxFyR48FZI89lcBFn8ggUP6rmkaWojbVKTdGX_vRFXUS8zMPPw8A6zB5alpKSgXJJ9sEQIi0Lyii7AUYyvCKFKMnYIFiXnmCDBlyA-2nGjYlLJOpiCUWk0LkE7TsFvTITGtT71ZrBqgN3sdLLeQeVaaJ3OdMxIZ5tgnR-20cY8hlN2ZUeE7zb1sN9OJujeDyamkOto1Qk46NQQzemuH4Pnm-un1V2xfri9X12tiwnLMhVad5I1gkpaVaphXStURxiimrSN5hyJskKtElhwrFrCNDZcdA1qeFMqoyUix-DyyzvNzWhanUMFNdRTsKMK29orW__dONvXL35TY8Ylpp-Ci50g-Lc5H1CPNmozDMoZP8eai0pwRsoMnv8DX_0cXD6uxiVFjFAqMnT2O85Pju9nkA_fhIwh</recordid><startdate>200604</startdate><enddate>200604</enddate><creator>Guven, Gulay S</creator><creator>Atalar, Enver</creator><creator>Yavuz, Bunyamin</creator><creator>Beyazit, Yavuz</creator><creator>Kekilli, Murat</creator><creator>Kilicarslan, Alparslan</creator><creator>Sahiner, Levent</creator><creator>Oz, Gul</creator><creator>Ozer, Necla</creator><creator>Aksoyek, Serdar</creator><creator>Haznedaroglu, Ibrahim C</creator><creator>Sozen, Tumay</creator><general>Elsevier Limited</general><general>National Medical Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>4T-</scope><scope>4U-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>200604</creationdate><title>Simvastatin treatment improves endothelial function and increases fibrinolysis in patients with hypercholestrolemia</title><author>Guven, Gulay S ; Atalar, Enver ; Yavuz, Bunyamin ; Beyazit, Yavuz ; Kekilli, Murat ; Kilicarslan, Alparslan ; Sahiner, Levent ; Oz, Gul ; Ozer, Necla ; Aksoyek, Serdar ; Haznedaroglu, Ibrahim C ; Sozen, Tumay</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p291t-ccf95b749488ab5fd7af3504c3dbc6607180da72762ad35c2e67fb0b6b1aec903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Anticholesteremic Agents - therapeutic use</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Endothelium, Vascular - physiopathology</topic><topic>Female</topic><topic>Fibrinolysis - drug effects</topic><topic>Humans</topic><topic>Hypercholesterolemia - drug therapy</topic><topic>Hypercholesterolemia - physiopathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prospective Studies</topic><topic>Simvastatin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guven, Gulay S</creatorcontrib><creatorcontrib>Atalar, Enver</creatorcontrib><creatorcontrib>Yavuz, Bunyamin</creatorcontrib><creatorcontrib>Beyazit, Yavuz</creatorcontrib><creatorcontrib>Kekilli, Murat</creatorcontrib><creatorcontrib>Kilicarslan, Alparslan</creatorcontrib><creatorcontrib>Sahiner, Levent</creatorcontrib><creatorcontrib>Oz, Gul</creatorcontrib><creatorcontrib>Ozer, Necla</creatorcontrib><creatorcontrib>Aksoyek, Serdar</creatorcontrib><creatorcontrib>Haznedaroglu, Ibrahim C</creatorcontrib><creatorcontrib>Sozen, Tumay</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>University Readers</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of the National Medical Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guven, Gulay S</au><au>Atalar, Enver</au><au>Yavuz, Bunyamin</au><au>Beyazit, Yavuz</au><au>Kekilli, Murat</au><au>Kilicarslan, Alparslan</au><au>Sahiner, Levent</au><au>Oz, Gul</au><au>Ozer, Necla</au><au>Aksoyek, Serdar</au><au>Haznedaroglu, Ibrahim C</au><au>Sozen, Tumay</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Simvastatin treatment improves endothelial function and increases fibrinolysis in patients with hypercholestrolemia</atitle><jtitle>Journal of the National Medical Association</jtitle><addtitle>J Natl Med Assoc</addtitle><date>2006-04</date><risdate>2006</risdate><volume>98</volume><issue>4</issue><spage>627</spage><epage>630</epage><pages>627-630</pages><issn>0027-9684</issn><eissn>1943-4693</eissn><coden>JNMAAE</coden><abstract>Statins reduce cardiovascular events by cholesterol-lowering as well as nonlipid-related actions. Thrombin activatable fibrinolysis inhibitor (TAFI) is a recently identified independent risk factor of thrombosis. Endothelial dysfunction is also a strong predictor of cardiovascular events. The aim of this study was to assess the effects of simvastatin treatment on circulating TAFI concentrations and endothelial function in patients with hypercholesterolemia.
Thirty-five patients (19 female, mean age 48 +/- 7 years) with hyperlipidemia were recruited into the study. Simvastatin was administered, 40 mg daily, for eight weeks to all subjects. Study subjects did not receive any medication except for lipid-lowering therapy during the follow-up period. Endothelial function was evaluated by flow-mediated dilation (FMD) from the brachial artery of the patients. Plasma lipid parameters, TAFI levels and endothelial function were measured before and after simvastatin treatment.
Treatment with simvastatin showed a significant decrement in plasma total cholesterol, LDL cholesterol and triglyceride levels (p<0.05). Plasma TAFI levels were also significantly decreased after simvastatin treatment [median 17.0 (range 0.4-93.7) mcg/mL versus median 6.9 (range 0.8-63.0) mcg/mL, p<0.001]. Mean FMD was measured 7.7 +/- 2.5% at baseline and significantly improved after treatment (13.0 +/- 1.4%) (p=0.001).
Our findings of decreased TAFI levels may reflect the beneficial effect of simvastatin treatment on fibrinolysis, and improved endothelial function may suggest the improved future cardiovascular events in hyperlipidemic patients.</abstract><cop>United States</cop><pub>Elsevier Limited</pub><pmid>16623076</pmid><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0027-9684 |
| ispartof | Journal of the National Medical Association, 2006-04, Vol.98 (4), p.627-630 |
| issn | 0027-9684 1943-4693 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2569240 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; PubMed Central |
| subjects | Anticholesteremic Agents - therapeutic use Endothelium, Vascular - drug effects Endothelium, Vascular - physiopathology Female Fibrinolysis - drug effects Humans Hypercholesterolemia - drug therapy Hypercholesterolemia - physiopathology Male Middle Aged Prospective Studies Simvastatin - therapeutic use |
| title | Simvastatin treatment improves endothelial function and increases fibrinolysis in patients with hypercholestrolemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T20%3A49%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Simvastatin%20treatment%20improves%20endothelial%20function%20and%20increases%20fibrinolysis%20in%20patients%20with%20hypercholestrolemia&rft.jtitle=Journal%20of%20the%20National%20Medical%20Association&rft.au=Guven,%20Gulay%20S&rft.date=2006-04&rft.volume=98&rft.issue=4&rft.spage=627&rft.epage=630&rft.pages=627-630&rft.issn=0027-9684&rft.eissn=1943-4693&rft.coden=JNMAAE&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1029337371%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=214053447&rft_id=info:pmid/16623076&rfr_iscdi=true |